---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-000553"
form_type: "8-K"
ticker: "RDNT"
cik: "0000790526"
company_name: "RadNet, Inc."
filed_at: "2022-01-28T23:59:59+00:00"
generated_at: "2026-06-27T14:28:25.255429+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# RadNet acquires Aidence and Quantib, outlines AI strategy for cancer screening and operations

## Summary
- Acquired Aidence (AI for lung cancer screening) and Quantib (AI for prostate MRI) to bolster AI portfolio.
- Conference call highlighted AI opportunities in clinical enhancements, business ops, and revenue growth.
- Dr. Greg Sorensen, CEO of DeepHealth, leads RadNet's AI division.
- Financial terms of the acquisitions were not disclosed in the filing.

## SEC filing metadata
- accession: 0001683168-22-000553
- form_type: 8-K
- ticker: RDNT
- cik: 0000790526
- company_name: RadNet, Inc.
- filed_at: 2022-01-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/790526/000168316822000553/0001683168-22-000553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/790526/000168316822000553/radnet_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-000553
- JSON: https://secwatch.observer/filing/0001683168-22-000553.json
- Plain text: https://secwatch.observer/filing/0001683168-22-000553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.